Loading…
HCW Biologics Inc. is projected to rise to $4.12 by 2027, a +23% move from its current price of $3.34. HCWB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.10 | $3.35 | $3.61 | +0.20% |
| Aug 6 | $3.01 | $3.35 | $3.73 | +0.40% |
| Aug 7 | $2.95 | $3.36 | $3.83 | +0.60% |
| Aug 8 | $2.90 | $3.37 | $3.91 | +0.80% |
| Aug 9 | $2.85 | $3.37 | $3.99 | +1.00% |
| Aug 10 | $2.81 | $3.38 | $4.07 | +1.20% |
| Aug 11 | $2.77 | $3.39 | $4.13 | +1.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.77 | $3.39 | $4.13 | +1.40% |
| Week 2 | $2.59 | $3.43 | $4.55 | +2.82% |
| Week 3 | $2.46 | $3.48 | $4.92 | +4.26% |
| Week 4 | $2.37 | $3.53 | $5.26 | +5.72% |
| Week 5 | $2.29 | $3.58 | $5.59 | +7.20% |
| Week 6 | $2.23 | $3.63 | $5.92 | +8.70% |
| Week 7 | $2.17 | $3.68 | $6.24 | +10.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd.
for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
HCWB is the publicly traded ticker for HCW Biologics Inc. and is currently priced at $3.15 with a market capitalization of $5.03M and a rank of 4996. The stock sits among the smaller names in the market by market cap and rank.
The price path forecast spans multiple years, showing a range of expected outcomes by year, with 2026 starting near the current level and gradual growth projected through 2050, including years labeled as bullish and others neutral. The forecast provides annual minimum, average, and maximum prices as well as ROI figures for each year.
A major floor 92.0% below — a decisive break under it would weaken the trend.
The nearest floor, 25.1% below — buyers have tended to step in here.
The nearest ceiling, 108.4% above — a clean break opens room to run.
A major ceiling 119.0% above — clearing it would confirm fresh momentum.
Key HCWB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HCWB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.83 | Buy | $2.99 | Buy |
| MA 10 | $3.01 | Buy | $3.10 | Buy |
| MA 20 | $3.70 | Sell | $3.21 | Buy |
| MA 50 | $2.70 | Buy | $2.71 | Buy |
| MA 100 | $1.59 | Buy | $2.20 | Buy |
| MA 200 | $1.73 | Buy | $2.91 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.09 | Neutral |
| Stoch RSI (14) | 39.51 | Neutral |
| CCI (20) | -47.58 | Neutral |
| Williams %R (14) | -65.00 | Info |
| MACD (12,26,9) | -0.18 | Sell |
| ROC (12) | -25.58 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 35.00 | Neutral |
| TRIX (15) | 1.07 | Buy |
| Awesome (5,34) | -0.24 | Sell |
| Ultimate (7,14,28) | 43.16 | Neutral |
| Momentum (10) | -0.80 | Sell |
| Aroon Osc (25) | 4.00 | Buy |
| Hull MA (9) | 2.88 | Buy |
| ADX (14) | 20.03 | Buy |
| ATR (14) | 0.24 | Info |
The 30-day technical picture for HCWB is NEUTRAL. The RSI(14) is 40, indicating modest momentum. The 50-day simple moving average sits at $6.95 and the 200-day simple moving average at $8.18, suggesting the price could trade toward the longer-term baseline if momentum shifts.
Support is noted at $2.50 and resistance at $6.96, with a 30-day price range from a low of $1.89 to a high of $5.25.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.61 | $3.34 | $5.40 | 0% | Neutral | |
| $3.00 | $4.12 | $6.10 | +23% | Bullish | |
| $2.74 | $4.00 | $6.33 | +20% | Neutral | |
| $2.24 | $3.45 | $5.73 | +3% | Neutral | |
| $2.15 | $3.46 | $5.99 | +4% | Neutral | |
| $2.08 | $3.51 | $6.29 | +5% | Neutral | |
| $2.21 | $3.88 | $7.17 | +16% | Neutral | |
| $2.95 | $5.41 | $10.29 | +62% | Bullish | |
| $2.78 | $5.29 | $10.32 | +58% | Bullish | |
| $2.14 | $4.24 | $8.46 | +27% | Bullish | |
| $2.84 | $6.31 | $13.83 | +89% | Bullish | |
| $3.92 | $8.71 | $20.02 | +161% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.61 | $3.34 | $4.09 | +0.00% |
| September 2026 | $3.00 | $3.65 | $4.62 | +9.17% |
| October 2026 | $3.25 | $4.00 | $5.18 | +9.79% |
| November 2026 | $3.21 | $4.00 | $5.26 | -0.18% |
| December 2026 | $3.22 | $4.05 | $5.40 | +1.35% |
Click any year to see its month-by-month HCWB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, HCWB is projected to trade between $1.61 and $5.40, averaging $3.34 — a potential gain of 0% from today's $3.34. A consolidation phase looks the most probable path here.
HCW Biologics Inc.'s 2027 outlook centres on $4.12, within a $3.00 to $6.10 range. That is up +23% on the projected 2026 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2028, HCWB could reach as high as $6.33, with a base case around $4.00 and support toward $2.74 — roughly +20% from $3.34. A consolidation phase looks the most probable path here.
Expect HCWB to range from $2.24 to $5.73 through 2029. The $3.45 average target implies a +3% move from current prices. That is -14% versus the projected 2028 average. Price action looks broadly range-bound.
The HCWB price prediction for 2030 points to an average of $3.46 (low $2.15, high $5.99) — a potential gain of +4% on today's $3.34. A consolidation phase looks the most probable path here.
In 2031, HCWB is projected to trade between $2.08 and $6.29, averaging $3.51 — a potential gain of +5% from today's $3.34. That is up +1% on the projected 2030 average. Price action looks broadly range-bound.
HCW Biologics Inc.'s 2032 outlook centres on $3.88, within a $2.21 to $7.17 range. That is up +11% on the projected 2031 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, HCWB could reach as high as $10.29, with a base case around $5.41 and support toward $2.95 — roughly +62% from $3.34. Momentum favours further upside here.
Expect HCWB to range from $2.78 to $10.32 through 2034. The $5.29 average target implies a +58% move from current prices. That is -2% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The HCWB price prediction for 2035 points to an average of $4.24 (low $2.14, high $8.46) — a potential gain of +27% on today's $3.34. Momentum favours further upside here.
In 2040, HCWB is projected to trade between $2.84 and $13.83, averaging $6.31 — a potential gain of +89% from today's $3.34. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
HCW Biologics Inc.'s 2050 outlook centres on $8.71, within a $3.92 to $20.02 range. That is up +38% on the projected 2040 average. That marks a +161% change versus current levels. Momentum favours further upside here.
Investing $1,000 in HCWB today (≈ 299.401198 HCWB) could be worth
$2,606.37
+$1,606.37 (+161%) by 2050 · US Dollar
Based on the average projected HCWB price of $8.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HCWBwould be worth at today's price.
$1,000 invested in HCWB on Jul 31, 2025 (≈ 235.849069 HCWB) would be worth
$787.74
-$212.26 (-21.2%) today · 0.79× · US Dollar
Based on a HCWB entry price of $4.24 vs. today's $3.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.5 | $1,336 | +33.6% |
| 1 month ago | $4.58 | $729.26 | -27.1% |
| 3 months ago | $0.452 | $7,389.38 | +638.9% |
| 6 months ago | $1.16 | $2,879.31 | +187.9% |
| 1 year ago | $4.24 | $787.74 | -21.2% |
| All time (5.0y) ago | $206 | $16.21 | -98.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HCWB forecast.
Our base-case forecast reaches $6.70 around 2050.
Implied market cap at $6.70: $10.7M
The multi-year forecast maps a path of fluctuating sentiment and growing averages over time. For 2026 the EPA-forecast shows an average price of $3.15 with a neutral stance and a minimum of $1.61 and a maximum of $5.15. In 2027 the average rises to $3.88 with a bullish outlook and a 23.2% ROI.
The 2028 forecast is neutral with an average of $3.74 and an ROI of 18.6%; 2029 shows an average of $3.29 with a 4.4% ROI. By 2030 the average is $3.26 with a 3.5% ROI and a neutral sentiment. The 2031–2032 period remains neutral but expands the range, with 2032 averaging $3.71 and a 17.7% ROI.
The outlook strengthens in 2033 (avg $5.12, ROI 62.6; bullish) and 2034 (avg $4.96, ROI 57.4; bullish). 2035 shows an average of $4.01 with a 27.4% ROI and bullish sentiment. The longer horizon includes 2040 with an average of $5.91 and a bullish stance, ROI 87.8, and 2050 with an average of $8.31, ROI 163.8, and bullish sentiment.
These figures illustrate potential upside but remain estimates, not guarantees, and are subject to risks and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.26, with a minimum of $2.02 and a maximum of $5.65, and a ROI of 3.5% with a neutral sentiment.
Forecasts show mixed results by year. The 2027 forecast indicates a bullish sentiment with an average of $3.88 and a ROI of 23.2%, while other years show more modest gains or neutral sentiment. These figures are estimates, not guarantees.
Yes. The 2032 forecast has a maximum of $6.86, and the 2033 forecast shows a maximum of $9.74, indicating the potential to exceed $6 in those years.
Current price is $3.15 and market cap is $5.03M.
For 2040, the average price is $5.91 with a maximum of $12.97 and a ROI of 87.8 in a bullish outlook. For 2050, the average is $8.31 with a maximum of $19.11 and a ROI of 163.8 in a bullish outlook.
HCW Biologics Inc. Community Discussion
0Share your HCW Biologics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.